A powerful alliance to usher in a new chapter for the biopharmaceutical industry in China and the United States.

  Recently, Zhejiang Yishengke Biotechnology Co., Ltd. (hereinafter referred to as "YSK"), focusing on core raw materials and technologies in the upstream of biopharmaceuticals, and Cytovance Biologics, a leading global biopharmaceutical CDMO service provider, jointly announced that they have officially signed a strategic cooperation agreement. Yishengke's culture media have already achieved over 100% improvement in the CHO antibody production process for its clients. In the future, the two companies will focus on key technologies in the biopharmaceutical industry—Fed-Batch and Perfusion CHO cell culture media—and conduct in-depth cooperation in the US market to jointly promote their development, optimization, and commercialization. This cooperation marks a solid step forward in collaborative innovation between Chinese and American biotechnology companies in the field of core process raw materials, aiming to provide global biopharmaceutical clients with more efficient, stable, and cost-effective cell culture solutions, accelerating the transition of innovative therapies from the laboratory to the market.

Working together to overcome process bottlenecks and empower biopharmaceutical development and production.

In the commercial production of biomacromolecules such as monoclonal antibodies and recombinant proteins, CHO cell culture is a core step, and the performance of the culture medium directly affects drug yield, quality, and production costs. Especially with the rise of continuous production processes and high-intensity processes such as perfusion culture, higher demands are placed on the formulation design and performance of culture media. According to the agreement, YSKwill leverage its extensive experience in culture medium formulation design, raw material research, and production processes to provide advanced basic culture medium formulations and technical support. Cytovance Biologics will utilize its rich experience in cell line development, process development, and large-scale production accumulated as a well-known CDMO, particularly its vast data on different product molecules and process platforms, to jointly optimize, test, and validate culture media in a targeted manner. The focus of the collaboration is:

• Customized Development: Developing dedicated fed-batch or perfusion culture media for specific client projects or popular technology platforms (such as high-yield clones, high-density perfusion) to maximize cell growth, product expression, and product quality.

• Platform Optimization: Optimizing existing culture medium platforms to improve their versatility and robustness across different CHO cell lines and production processes, helping clients shorten process development time.

• Localization Promotion and Service in the United States: The two parties will join forces to promote the product in the US market and, relying on Cytovance's local service network, provide customers with fast and professional technical support and application guidance.

About us

Founded in 2013, YSK BIOSCIENCES is at the forefront of research and development, specializing in the production of high-quality serum-free media and chromatography resins for protein and antibody purification. We are dedicated to providing exceptional products to biopharmaceutical companies involved in antibodies, vaccines, Cell and Gene Therapy (CGT) and cultivated meat technology companies.

Our production capabilities include a single batch capacity of 40,000 liters for culture media and 1,000 liters for chromatography resins. Our comprehensive range of upstream and downstream products, coupled with stringent quality control measures, fully satisfies the diverse requirements of our clients across various sectors. With over a decade of innovation and R&D, YSK's forward-thinking approach and premium products have cemented long-term partnerships with numerous domestic enterprises and research institutions in the biopharmaceutical industry.

Cytovance Biologics

Cytovance Biologics is a leader in the development and manufacturing of clinical and commercial large molecule APIs from mammalian cell culture, microbial fermentation, and plasmid DNA.

Cytovance delivers scientific rigor, a solutions-oriented mindset, and ingenuity end-to-end. When combined with our comprehensive service portfolio of strain and cell line development process development, analytical capabilities, cell banking, scale-up, CGMP manufacturing, program management, and lifecycle support, we are able to support products throughout the journey from R&D to regulatory approval and commercial production. Our team’s approach and breadth of knowledge have led to our high success rate and multiple client products on the market, actively making the world a healthier place.